{"nctId":"NCT01218997","briefTitle":"ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)","startDateStruct":{"date":"2003-08"},"conditions":["Alcoholism"],"count":436,"armGroups":[{"label":"Medisorb naltrexone 380 mg (VIVITROL)","type":"EXPERIMENTAL","interventionNames":["Drug: Medisorb naltrexone 380 mg"]},{"label":"Oral naltrexone 50 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Oral naltrexone 50 mg"]}],"interventions":[{"name":"Medisorb naltrexone 380 mg","otherNames":["VIVITROL® 380 mg","Naltrexone for extended-release injectable suspension"]},{"name":"Oral naltrexone 50 mg","otherNames":["Revia®"]}],"eligibilityModule":{"eligibilityCriteria":"Primary Inclusion Criteria:\n\n* Current diagnosis of DSM-IV alcohol dependence and/or diagnosis of DSM-IV opiate dependence within 3 months prior to screening\n* 18 years or older\n* Desire to seek treatment for alcohol and/or opiate abuse/dependence\n* Agree to use contraception for the study duration if of childbearing potential\n* Written informed consent and willingness to perform study procedures\n* Stable address and phone and at least 1 source of contact information (eg, family member, significant other)\n\nPrimary Exclusion Criteria:\n\n* Presence of opiates in the urine (as determined by urine drug test) on Day 0 prior to naltrexone treatment\n* Clinically significant medical/psychological condition or abnormality at screening (ie, physical examination, electrocardiogram \\[ECG\\], hematology or blood chemistry evaluation, or urinalysis findings)\n* Clinically significant active hepatitis or hepatic failure evidenced by 1 of the following: aspartate transaminase (AST) or alanine transaminase (ALT) higher than 3 times the upper limit of normal (3xULN), hyperbilirubinemia (bilirubin \\>10% above ULN), creatine phosphokinase (CPK) higher than 10xULN, prolonged prothrombin time(international normalized ratio ≥1.7), ascites, or esophageal variceal disease\n* Manifestation of suicidal ideation, psychotic symptoms (including significant violent behavior), or psychiatric disorders that would compromise ability to complete the study\n* Participation in a formal methadone program currently or within prior 3 years\n* More than 2 prior medically supervised detoxification treatments in prior 3 years\n* Pregnancy or lactation\n* Current prescribed opiate therapy, or receipt of opiates within 7 days prior to study drug dosing, or ongoing medical condition likely to require prescribed opiate therapy during study period\n* Failed naloxone challenge on Day 0 (the challenge could be repeated up to 2 times, with at least 24 hours between attempts)\n* Participation in a clinical trial within 30 days of screening\n* Previous enrollment in a VIVITROL clinical trial\n* Receipt of any drug product administered as a gluteal injection within 180 days prior to Day 0 or anticipated need for gluteal injections during study period\n* Intolerance and/or hypersensitivity to naltrexone, naloxone, or polylactide-co-polymers such as polylactide-co-glycolide (PLG)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While on Study","description":"A TEAE was defined as any adverse event (AE) that started or worsened on or after the administration of the first dose of study medication through 30 days after the end of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"336","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":49,"n":371},"commonTop":["Nausea","Headache NOS","Nasopharyngitis","Insomnia","Upper respiratory tract infection NOS"]}}}